ASCO26: Blood cancer readouts take centre stage
Summary
This article reviews notable blood cancer data presented at ASCO 2026. It covers BeOne’s long-term Brukinsa results in chronic lymphocytic leukaemia, Karyopharm’s SENTRY data for Xpovio in myelofibrosis, and Cellectar’s positive WM readout for iopofosine I 131. It also highlights late-stage developments from AstraZeneca and Regeneron in AL amyloidosis. The piece centers on trial outcomes, efficacy signals, and safety profiles across several hematology programs.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected